News

The late-breaking clinical research that will be presented at New York Valves will unveil the latest advances in transcatheter aortic valve replacement, alongside innovations in mitral and tricuspid devices and techniques.

According to findings from animal studies, the inflammatory reaction plays an important role after an infarction and has a decisive influence on whether the functions of the heart muscle are restored.

“In recent years, with disease and contamination issues disrupting the global supply chain of pig heparin and potentially putting millions of patients at risk, it’s clear we need to diversify the way we make this drug,” said Jonathan Dordick,...

Aerobic training is known to regulate blood pressure more effectively when practiced in the evening than in the morning. Researchers who conducted a study of elderly patients at the University of São Paulo’s School of Physical Education and...

The results: Across all pulmonary hypertension groups, average pulmonary arterial pressure decreased with greater lifetime duration of menses. Use of HRT was associated with lower mean pulmonary artery pressure and higher right ventricular...

Professor Serruys, Chairman & study director of the LANDMARK trial, said, "Myval THV series are novel next-gen THV devices; non-inferior to the Sapien and Evolut THV series. Myval THV series have a unique size matrix incorporating...

SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of CIEDs, including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices...

DESyne BDS Plus has a bioresorbable coating containing three drugs: two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor (sirolimus) designed for delivery of site-specific antithrombotic therapeutic.

The novel LithiX Hertz Contact Intravascular Lithotripsy (IVL) system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal...

Elixir Medical announced two-year results from the BIOADAPTOR randomized controlled (1:1) trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent from 34 centers in Japan, Europe, and New...